215 related articles for article (PubMed ID: 23763460)
21. Whole-body positron emission tomography/computed tomography imaging and staging of orbital lymphoma.
Roe RH; Finger PT; Kurli M; Tena LB; Iacob CE
Ophthalmology; 2006 Oct; 113(10):1854-8. PubMed ID: 16860867
[TBL] [Abstract][Full Text] [Related]
22. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP
Borchmann P; Haverkamp H; Lohri A; Mey U; Kreissl S; Greil R; Markova J; Feuring-Buske M; Meissner J; Dührsen U; Ostermann H; Keller U; Maschmeyer G; Kuhnert G; Dietlein M; Kobe C; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Engert A
Lancet Oncol; 2017 Apr; 18(4):454-463. PubMed ID: 28236583
[TBL] [Abstract][Full Text] [Related]
23. The role of FDG-PET scanning in assessing lymphoma in 2012.
Bodet-Milin C; Eugène T; Gastinne T; Bailly C; Le Gouill S; Dupas B; Kraeber-Bodéré F
Diagn Interv Imaging; 2013 Feb; 94(2):158-68. PubMed ID: 23295044
[TBL] [Abstract][Full Text] [Related]
24. Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring.
Minamimoto R; Fayad L; Advani R; Vose J; Macapinlac H; Meza J; Hankins J; Mottaghy F; Juweid M; Quon A
Radiology; 2016 Jul; 280(1):220-9. PubMed ID: 26854705
[TBL] [Abstract][Full Text] [Related]
25. Prediction of outcome in pediatric Hodgkin lymphoma based on interpretation of
Isik EG; Kuyumcu S; Kebudi R; Sanli Y; Karakas Z; Cakir FB; Unal SN
Ann Nucl Med; 2017 Nov; 31(9):660-668. PubMed ID: 28741053
[TBL] [Abstract][Full Text] [Related]
26. PET/CT: appropriate application in lymphoma.
Wang X
Chin Clin Oncol; 2015 Mar; 4(1):4. PubMed ID: 25841711
[TBL] [Abstract][Full Text] [Related]
27. The Deauville 5-Point Scale Improves the Prognostic Value of Interim FDG PET/CT in Extranodal Natural Killer/T-Cell Lymphoma.
Jiang C; Su M; Kosik RO; Zou L; Jiang M; Tian R
Clin Nucl Med; 2015 Oct; 40(10):767-73. PubMed ID: 26164182
[TBL] [Abstract][Full Text] [Related]
28. The impact of fluorodeoxyglucose-positron emission tomography in primary staging and patient management in lymphoma patients.
Allen-Auerbach M; de Vos S; Czernin J
Radiol Clin North Am; 2008 Mar; 46(2):199-211, vii. PubMed ID: 18619376
[TBL] [Abstract][Full Text] [Related]
29. The role of FDG-PET imaging in the management of lymphoma.
Kostakoglu L; Leonard JP; Coleman M; Goldsmith SJ
Clin Adv Hematol Oncol; 2004 Feb; 2(2):115-21. PubMed ID: 16163171
[TBL] [Abstract][Full Text] [Related]
30. Time to Prepare for Risk Adaptation in Lymphoma by Standardizing Measurement of Metabolic Tumor Burden.
Barrington SF; Meignan M
J Nucl Med; 2019 Aug; 60(8):1096-1102. PubMed ID: 30954945
[TBL] [Abstract][Full Text] [Related]
31. PET imaging for response assessment in lymphoma: potential and limitations.
Schöder H; Moskowitz C
Radiol Clin North Am; 2008 Mar; 46(2):225-41, viii. PubMed ID: 18619378
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of metabolic tumor burden by positron emission tomography/computed tomography in patients with relapsed/refractory diffuse large B-cell lymphoma.
Tateishi U; Tatsumi M; Terauchi T; Ando K; Niitsu N; Kim WS; Suh C; Ogura M; Tobinai K
Cancer Sci; 2015 Feb; 106(2):186-93. PubMed ID: 25495273
[TBL] [Abstract][Full Text] [Related]
33. [Values of Different Evaluation Criteria of Interim
Zhu LT; Cen XN; Ou JP; Qiu ZX; Wang LH; Liu W; Wang WS; Dong YJ; Liang ZY; Wang MJ; Xu WL; Sun YH; Wang Q; Yin Y; Ren HY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):431-437. PubMed ID: 28446288
[TBL] [Abstract][Full Text] [Related]
34. Using PET-CT in the restaging of primitive mediastinal B-cell lymphoma (PMBCL) after chemotherapy: which criteria should we use?
Giunta F; Zotta M; Menga M; Balma M; Bellò M; Passera R; Filippi AR; Chiappella A; Ladetto M; Ricardi U; Vitolo U; Bisi G
Q J Nucl Med Mol Imaging; 2015 Jun; 59(2):214-9. PubMed ID: 25669764
[TBL] [Abstract][Full Text] [Related]
35. [Malignant lymphoma].
Okamoto R
Gan To Kagaku Ryoho; 2009 Dec; 36(13):2532-6. PubMed ID: 20009452
[TBL] [Abstract][Full Text] [Related]
36. The prevalence and clinical significance of (18) F-2-fluoro-2-deoxy-D-glucose (FDG) uptake in the thyroid gland on PET or PET-CT in patients with lymphoma.
Lin M; Wong C; Lin P; Shon IH; Cuganesan R; Som S
Hematol Oncol; 2011 Jun; 29(2):67-74. PubMed ID: 20635328
[TBL] [Abstract][Full Text] [Related]
37. Comparison between whole-body MRI with diffusion-weighted imaging and PET/CT in staging newly diagnosed FDG-avid lymphomas.
Albano D; Patti C; La Grutta L; Agnello F; Grassedonio E; Mulè A; Cannizzaro G; Ficola U; Lagalla R; Midiri M; Galia M
Eur J Radiol; 2016 Feb; 85(2):313-8. PubMed ID: 26781135
[TBL] [Abstract][Full Text] [Related]
38. The value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for staging of primary extranodal head and neck lymphomas.
Schrepfer T; Haerle SK; Strobel K; Schaefer N; Hälg RA; Huber GF
Laryngoscope; 2010 May; 120(5):937-44. PubMed ID: 20422687
[TBL] [Abstract][Full Text] [Related]
39. FDG PET/CT imaging as a biomarker in lymphoma.
Meignan M; Itti E; Gallamini A; Younes A
Eur J Nucl Med Mol Imaging; 2015 Apr; 42(4):623-33. PubMed ID: 25573631
[TBL] [Abstract][Full Text] [Related]
40. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas.
Specht L
Semin Radiat Oncol; 2007 Jul; 17(3):190-7. PubMed ID: 17591566
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]